Eric Coldwell
Stock Analyst at Baird
(3.84)
# 712
Out of 5,042 analysts
188
Total ratings
60.58%
Success rate
6.03%
Average return
Main Sectors:
Stocks Rated by Eric Coldwell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: Outperform | $9 → $14 | $11.30 | +23.89% | 9 | Sep 3, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $222 → $224 | $178.11 | +25.76% | 22 | Sep 2, 2025 | |
| DGX Quest Diagnostics | Downgrades: Neutral | $194 | $182.18 | +6.49% | 11 | Aug 25, 2025 | |
| PINC Premier | Maintains: Neutral | $22 → $27 | $28.12 | -3.98% | 9 | Aug 20, 2025 | |
| CAH Cardinal Health | Maintains: Outperform | $197 → $203 | $161.89 | +25.39% | 13 | Aug 13, 2025 | |
| OMI Owens & Minor | Maintains: Outperform | $10 → $7 | $5.51 | +27.04% | 19 | Aug 12, 2025 | |
| LH Labcorp Holdings | Maintains: Outperform | $290 → $302 | $279.49 | +8.05% | 14 | Jul 25, 2025 | |
| MEDP Medpace Holdings | Maintains: Neutral | $313 → $490 | $605.20 | -19.04% | 19 | Jul 23, 2025 | |
| IQV IQVIA Holdings | Maintains: Neutral | $159 → $196 | $220.52 | -11.12% | 18 | Jul 23, 2025 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $118 → $140 | $197.04 | -28.95% | 14 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $16 | $9.37 | +70.76% | 10 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $531 → $688 | $801.67 | -14.18% | 17 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $45 | $61.49 | -26.82% | 2 | Jun 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $66 | $81.93 | -19.44% | 7 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $46 | $1.51 | +2,946.36% | 4 | Nov 10, 2017 |
Fortrea Holdings
Sep 3, 2025
Maintains: Outperform
Price Target: $9 → $14
Current: $11.30
Upside: +23.89%
ICON Public Limited Company
Sep 2, 2025
Maintains: Outperform
Price Target: $222 → $224
Current: $178.11
Upside: +25.76%
Quest Diagnostics
Aug 25, 2025
Downgrades: Neutral
Price Target: $194
Current: $182.18
Upside: +6.49%
Premier
Aug 20, 2025
Maintains: Neutral
Price Target: $22 → $27
Current: $28.12
Upside: -3.98%
Cardinal Health
Aug 13, 2025
Maintains: Outperform
Price Target: $197 → $203
Current: $161.89
Upside: +25.39%
Owens & Minor
Aug 12, 2025
Maintains: Outperform
Price Target: $10 → $7
Current: $5.51
Upside: +27.04%
Labcorp Holdings
Jul 25, 2025
Maintains: Outperform
Price Target: $290 → $302
Current: $279.49
Upside: +8.05%
Medpace Holdings
Jul 23, 2025
Maintains: Neutral
Price Target: $313 → $490
Current: $605.20
Upside: -19.04%
IQVIA Holdings
Jul 23, 2025
Maintains: Neutral
Price Target: $159 → $196
Current: $220.52
Upside: -11.12%
Charles River Laboratories International
May 8, 2025
Maintains: Neutral
Price Target: $118 → $140
Current: $197.04
Upside: -28.95%
Feb 27, 2025
Maintains: Outperform
Price Target: $14 → $16
Current: $9.37
Upside: +70.76%
Nov 7, 2024
Upgrades: Outperform
Price Target: $531 → $688
Current: $801.67
Upside: -14.18%
Jun 26, 2020
Maintains: Neutral
Price Target: $35 → $45
Current: $61.49
Upside: -26.82%
May 7, 2020
Maintains: Neutral
Price Target: $62 → $66
Current: $81.93
Upside: -19.44%
Nov 10, 2017
Maintains: Outperform
Price Target: $67 → $46
Current: $1.51
Upside: +2,946.36%